A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 8, 2010

Liver Damage Increases Tenofovir-Induced Kidney Impairment Risk

People coinfected with both HIV and hepatitis B virus (HBV) who have more significant liver damage (fibrosis) are much more likely to develop mild kidney problems after starting tenofovir (found in Viread, Truvada and Atripla) than people with little liver damage. These data were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases, held October 29 to November 2 in Boston.

The antiretroviral (ARV) drug tenofovir—which is used to treat both HIV and HBV—has a rare but well-studied side effect: tubular kidney damage. In most people, reduced kidney function is mild to moderate. In just under 1 percent of people who take tenofovir, however, tubular kidney damage can be more severe and occasionally life-threatening. While rates of kidney damage in people with either HIV or HBV have been assessed—serious liver disease can affect the organ’s ability to handle toxins and blood flow, which can put a strain on the kidneys—little is known about the effect of liver fibrosis on the risk of developing tenofovir-induced kidney problems in people infected with both viruses.

To address this unanswered question, Anders Boyd, MPH, from the Hospital Saint Antoine in Paris, and his colleagues followed 137 HIV and HBV coinfected individuals after they started tenofovir therapy. All study participants had taken ARV drugs before. Their average age was 41, and about 90 percent were male. The average amount of time spent on tenofovir during the study was 34 months.

All participants underwent a liver biopsy before starting tenofovir, and 41 were found to have severe liver fibrosis and 96 to have mild liver fibrosis. Kidney function at 12, 24 and 36 months after starting tenofovir was measured by assessing the participants’ estimated glomerular filtration rate (eGFR).

Boyd and his colleagues found that liver fibrosis had a profound effect on the likelihood of having reduced kidney function after starting tenofovir. In fact, those who started tenofovir with the most liver fibrosis were 3.74 times more likely to have mild kidney impairment than those with little fibrosis. The greatest difference in kidney function between those with high and low fibrosis scores occurred within the first two years of treatment.

People with more severe liver disease are at increased risk for kidney dysfunction, regardless of whether they use tenofovir. To determine the actual contribution of tenofovir to this problem, future studies would need to compare individuals with high fibrosis scores who start tenofovir with similar people who do not take tenofovir.

“HIV and HBV coinfected patients treated with tenofovir are at higher risk of [kidney] impairment when exhibiting high liver fibrosis levels, and thereby warranting closer follow-up of [kidney function] in this patient population,” the authors concluded.

Search: AASLD, tenofovir, Viread, Truvada, Atripla, Renal, kidney, liver, fibrosis, hepatitis B virus, HBV, Anders Boyd

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.